Related Experiment Videos
Thrombopoietin-producing hepatocellular carcinoma
Tomiko Ryu1, Satoshi Nishimura, Hideaki Miura
1Department of Internal Medicine, Social Insurance Chuo General Hospital, Tokyo.
Internal Medicine (Tokyo, Japan)
|August 20, 2003
Summary
Hepatocellular carcinoma (HCC) can cause thrombocytosis by producing thrombopoietin (TPO). Despite high TPO levels, platelet counts may paradoxically decrease in advanced stages.
Area of Science:
- Oncology
- Hematology
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer.
- Thrombocytosis, an elevated platelet count, can be associated with various cancers.
- Thrombopoietin (TPO) is a key regulator of platelet production.
Observation:
- A 66-year-old male patient with HCC presented with marked thrombocytosis.
- Bone marrow aspirates showed increased mature megakaryocytes (MgK).
- Serum TPO levels were significantly elevated, approximately 100-fold normal, in the terminal stage.
Findings:
- Despite elevated TPO and initial thrombocytosis, the patient's platelet count decreased significantly in the terminal phase.
- Autopsy revealed normoplastic bone marrow with decreased, immature MgK and no tumor cells.
- Immunohistochemical staining indicated TPO production by HCC cells, not hepatocytes.
Implications:
- This case suggests that HCC can be a source of TPO production.
- The decrease in platelet count despite high TPO warrants further investigation into TPO resistance or consumption mechanisms in advanced HCC.
- Understanding TPO production in HCC may offer insights into paraneoplastic syndromes and potential therapeutic targets.